Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Michael B. Maurin"'
Publikováno v:
AAPS PharmSciTech. 4:99-108
The purpose of this research is to investigate the sublimation process of DPC 963, a second-generation nonnucleoside reverse transcriptase inhibitor for HIV-1 retrovirus, and to better understand the effect of sublimation during active pharmaceutical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a916cfb3e3377943b6248c28e87f386d
https://doi.org/10.1208/pt040223
https://doi.org/10.1208/pt040223
Autor:
C. M. Foris, Shelley R. Rabel, G. Creston Campbell, Gregory A. Nemeth, Susan M. Rowe, Michael B. Maurin, J. Gerry Everlof, Rodney Vickery
Publikováno v:
Journal of Pharmaceutical Sciences. 91:2599-2604
Roxifiban was found to exist in two polymorphic forms. The polymorphs were detected by X-ray powder diffraction and solid-state carbon nuclear magnetic resonance. A slight difference between the two polymorphs was also detected by isothermal microcal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9eced34e748fdc6094b327cf22de55d9
https://doi.org/10.1002/jps.10078
https://doi.org/10.1002/jps.10078
Publikováno v:
Journal of Pharmaceutical and Biomedical Analysis. 30:125-129
Roxifiban, an experimental antithrombotic prodrug, exists as crystalline forms I and II. A quantitative solid-state nuclear magnetic resonance (NMR) method was developed to characterize the two polymorphs of roxifiban. The differences in the NMR spec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e65c38d4a0fa565f4c39cc0ebda8198
https://doi.org/10.1016/s0731-7085(02)00203-0
https://doi.org/10.1016/s0731-7085(02)00203-0
Publikováno v:
Pharmaceutical Research. 19:517-521
Purpose. To determine the kinetics and mechanism of hydrolysis of efavirenz [(S)-6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one] in aqueous solutions. Methods. The solution stability was examined at 60°C and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e654f59e4a702578b36f8e79b35635b9
https://doi.org/10.1023/a:1015160132290
https://doi.org/10.1023/a:1015160132290
Publikováno v:
AAPS PharmSci. 3:26-29
The solubility of 4 analogues of efavirenz was studied as a function of pH. The study evaluated the ionization behavior and determined the relative contribution of electronegative substituents versus resonance effects on the pK(a) value of the cyclic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42b9aeb1099e33d9f880e5430a522dd5
https://doi.org/10.1208/ps030428
https://doi.org/10.1208/ps030428
Autor:
Anita Taylor, Michael B. Maurin
Publikováno v:
Journal of Pharmaceutical and Biomedical Analysis. 23:1065-1071
The effect of variable heating rates on the efficiency or resolution of the derivative of the thermogravimetry profiles of three model pharmaceutical compounds was investigated. The variable heating system utilized computer controlled algorithms for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95cc78d652ab49198cd0ff50e0fd357d
https://doi.org/10.1016/s0731-7085(00)00368-x
https://doi.org/10.1016/s0731-7085(00)00368-x
Autor:
T.M. Sielecki, R.D. Vickery, C. M. Foris, R.E. Olson, Z. G. Li, R. L. Harlow, Michael B. Maurin, L. Liang, Junke Liu
Publikováno v:
Journal of Pharmaceutical Sciences. 89:1237-1242
In the course of the development of Lumaxis™ (roxifiban), the physical state of XP280 (the besylate salt of the active metabolites of roxifiban) and SC887 (the mesylate salt of the free base of roxifiban) were characterized. Powder X‐ray diffract
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ace9d527940d7227aa9e4c1ea0cf8136
https://doi.org/10.1002/1520-6017(200010)89:10<1237::aid-jps1>3.0.co
https://doi.org/10.1002/1520-6017(200010)89:10<1237::aid-jps1>3.0.co
Publikováno v:
Pharmaceutical Research. 13:481-484
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c75733228a14e74d5769a4d8de2adb7b
https://doi.org/10.1023/a:1016021432262
https://doi.org/10.1023/a:1016021432262
Publikováno v:
International Journal of Pharmaceutics. 144:99-106
DMP 323 ([4R-(4α, 5α, 6β, 7β)]-hexahydro-5,6-bis(hydroxy)-1,3-bis ([(4-hydroxymethyl)phenyl]methyl)-4,7-bis(phenylmethyl)-2H-1,3-diazepin-2-one), a potent inhibitor of HIV protease and HIV replication, is a white irregular-shaped nonhygroscopic c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a4627f4fda056233a8d692d1431686df
https://doi.org/10.1016/s0378-5173(96)04732-1
https://doi.org/10.1016/s0378-5173(96)04732-1
Publikováno v:
Pharmaceutical Research. 13:1401-1405
Purpose. The solubility behavior, phase transition and inhibition of the nucleation process of etanidazole were characterized. Methods. Solubility measurements as a function of time permitted characterization of the solubility behavior and phase tran
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a21924059baedfa342a05948d849c79d
https://doi.org/10.1023/a:1016038403921
https://doi.org/10.1023/a:1016038403921